Pharmacovigilance is the systematic monitoring, collection, and assessment of adverse events and other safety data for medicines, vaccines, and biologics after they reach the market. In life science translation, the term appears in safety reports, risk management plans, periodic benefit-risk evaluations, aggregate reports, and local regulatory submissions that must be aligned with national reporting requirements, timelines, and local language conventions.
This term appears in pharmacovigilance agreements, periodic safety update reports, individual case safety reports, risk management plans, and local health authority portals that translation teams localize for different markets. Translators must keep event descriptions, causality terms, seriousness criteria, and medical narratives consistent, because regulators compare source and translated safety data during inspections, labeling updates, and submissions.
A common error is translating 'adverse event' and 'adverse reaction' interchangeably because they are near-synonyms in everyday language, but in pharmacovigilance they have distinct causality implications and regulatory definitions. Another error is normalizing or softening seriousness terms such as 'life-threatening' or 'medically significant,' which can change expedited reporting obligations, understate risk, and delay safety signals.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →